Trial Profile
A phase I study of the combination of oral DJ-927 [tesetaxel] and capecitabine in patients with advanced solid tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions
- 15 May 2012 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 25 Oct 2007 Status changed from suspended to completed.
- 24 Sep 2005 New trial record.